Skip to content

Alligator Bioscience

  •  
    • Se
  • Startpage
  • About Alligator
    • Board of Directors
    • Management
    • Career
  • Research and development
    • Immunotherapy of cancer
    • Pipeline
      • Mitazalimab
      • Neo-X-PrimeTM
      • ALG.APV-527
      • ATOR-1017
      • Research projects
    • Scientific publications
    • Technology platform
      • Alligator-GOLD®
      • Alligator-FABTM
      • FIND®
    • Scientific advisors
  • Corporate governance
    • General meeting
    • Board of Directors and Management
    • Nomination Committee
    • Audit Committee
    • Remuneration Committee
    • Remuneration
    • Auditors
    • Articles of association
    • Internal control
  • Investors
    • Share and owner information
    • Sharegraph
    • Analysts
    • Preferential Rights Issue Q4 2021
    • Preferential Rights Issue Q1 2021
    • IPO
    • Financial reports
      • Interim reports
      • Year End Reports
      • Annual reports
    • Financial calendar
    • Presentations
  • Business Development
  • News
  • Press releases
  • Contact
  • Events

  1. Startpage
  2. News
  3. PR
Key downloads
Alligator Bioscience AB reports financial results for the first 9 months of the year and for Q3 2022 and provides a business updateAlligator Bioscience AB reports H1 2022 and Q2 2022 financial results and provides a business updateBulletin from the annual general meeting in Alligator Bioscience AB on May 5, 2022Interim report January–March 2022Alligator Bioscience publishes Annual Report for 2021
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
All IRRegulatoryReport
View as grid View as list
2018-10-022022-09-20

CEO Per Norlén comments on the Nobel Prize in Physiology or Medicine 2018

Tasuku Honjo & James Allison share the 2018 Nobel Prize in Physiology or Medicin. Photo: Wikimedia CommonsOn Monday October 1st the Nobe ...
Continue reading
2016-07-082022-09-20

Alligator contracts BioInvent for process development and cGMP manufacturing of the immuno-oncology drug candidate ADC-1015

Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for tumor-directed immunotherapy. ...
Continue reading
2016-05-202022-09-20

Alligator receives the SwedenBIO Award!

Alligator Bioscience has received the SwedenBIO Award for ”exceptional achievements within the life-science industry”. This is yet another c ...
Continue reading
2016-04-222022-09-20

First milestone payment for ADC-1013

Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of canc ...
Continue reading
2016-03-302022-09-20

Documentation of proposals for the annual shareholder’s meeting

After proofreading minor corrections has been made. Comprehensive income and Financial position are however intact. Complete proposal, item ...
Continue reading
2016-03-042022-09-20

Communication of proposals for the extraordinary shareholder’s meeting on 14 March, 2016

Major shareholders have now submitted their proposals regarding items 8 and 9 in the published notice. Proposal item 8: The number of board ...
Continue reading
2016-02-152022-09-20

Notice of extraordinary shareholders’ meeting in Alligator Bioscience AB

The shareholders of Alligator Bioscience AB (publ), Reg. No 556597-8201, are hereby invited to attend the extraordinary shareholder’s meetin ...
Continue reading
2015-08-122022-09-20

Alligator Bioscience Announces Collaboration with Johnson & Johnson Innovation for the CD40 Agonistic Immuno-Oncology Antibody ADC-1013

Alligator Bioscience AB, a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer ...
Continue reading
2015-04-272022-09-20

First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial

First Patient Dosed by Alligator Bioscience in a Clinical Phase 1 Multicenter Trial in Advanced Solid Tumors with the CD40 Agonistic Immuno- ...
Continue reading

Posts navigation

Older posts
  1. Startpage
  2. News
  3. PR
About Alligator

Alligator develops antibody-based pharmaceuticals for cancer treatment. The company specializes in the development of tumor-directed immunotherapies, in particular agonistic mono- and bispecific antibodies. The company is active in the early stages of drug development, from idea to clinical phase 2 studies and beyond.

Alligator Bioscience has global headquarters in Lund, Sweden, and is listed on Nasdaq Stockholm (ticker: ATORX).

Links
  • About Alligator
  • R&D
  • Corporate governance
  • Investors
  • News
  • Business Development
  • Privacy Policy
Contact us

Alligator Bioscience AB Medicon Village Scheelevägen 2 SE-223 81 Lund Sweden

Phone:
+ 46 (0)46 540 82 00

info@alligatorbioscience.com
ir@alligatorbioscience.com
bd@alligatorbioscience.com

Follow us

  

Email subscription

Subscribe to get our pressreleases and investor alerts by email from Alligator Bioscience.

Subscribe

  • © Copyright 2019 – Alligator Bioscience AB

  • Privacy Policy | Use of Cookies |  Change your cookie settings here.

  • Disclaimer Market data could be delayed. Delivered by Modular Finance.

Cookies
We use cookies for administering, monitoring and optimizing the website, and for analytical purposes, in accordance with what is stated in our cookie policy.
Settings Accept all
Cookies
Do your settings below. Or read our cookie policy.
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all